TY - JOUR
T1 - Trends in net survival lung cancer in six European Latin countries
T2 - Results from the SUDCAN population-based study
AU - GRELL EUROCARE-5 Working Group
AU - Bordoni, Andrea
AU - Uhry, Zoé
AU - Antunes, Luis
AU - Van Eycken, E.
AU - Henau, K.
AU - Velten, M.
AU - Bouvier, V.
AU - Launoy, G.
AU - Bouvier, A. M.
AU - Faivre, J.
AU - Woronoff, A. S.
AU - Robaszkiewicz, M.
AU - Tretarre, B.
AU - Bossard, N.
AU - Colonna, M.
AU - Molinié, F.
AU - Bara, S.
AU - Lapôtre-Ledoux, B.
AU - Grosclaude, P.
AU - Brenner, H.
AU - Katalinic, A.
AU - Mazzoleni, G.
AU - Bulatko, A.
AU - Buzzoni, C.
AU - Giacomin, A.
AU - Ferretti, S.
AU - Barchielli, A.
AU - Manneschi, G.
AU - Gatta, G.
AU - Sant, M.
AU - Amash, H.
AU - Amati, C.
AU - Baili, P.
AU - Berrino, F.
AU - Bonfarnuzzo, S.
AU - Botta, L.
AU - Capocaccia, R.
AU - Di Salvo, F.
AU - Foschi, R.
AU - Margutti, C.
AU - Meneghini, E.
AU - Minicozzi, P.
AU - Trama, A.
AU - Serraino, D.
AU - Zucchetto, A.
AU - De Angelis, R.
AU - Caldora, M.
AU - Carrani, E.
AU - Francisci, S.
AU - Verne, Julia
N1 - Funding Information:
The SUDCAN study was supported by the French Ligue contre le Cancer. The authors thank EUROCARE for providing the data, Ludivine Garrier (registre des cancers digestifs de Bourgogne) for her technical assistance and Jean Iwaz (Service de Biostatistique des Hospices Civils de Lyon) for the final revision of the manuscript. The EUROCARE study was supported by The Compagnia di San Paolo, Fondazione Cariplo, the Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and the European Commission (European Action Against Cancer, EPAAC, Joint Action No. 20102202).
Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Survival is a key measure of the effectiveness of a healthcare system. European Latin countries have some similarities in their health systems; it is thus interesting to examine their differences in survival from cancer, here, lung cancer. The aim of the SUDCAN collaborative study was to compare the trends in the 1- and 5-year net survival from lung cancer and the trends in the excess mortality rates between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland). The data were extracted from the EUROCARE-5 database. First, the net survival was studied over the 2000-2004 period using Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. The analyses were carried out using a flexible excess rate modelling. Overall, the 1-year net survival from lung cancer ranged between 36 (Spain) and 43% (Belgium and Switzerland) and the 5-year net survival ranged between 11 (Spain) and 15% (Belgium and Switzerland). Between 1992 and 2004, the age-standardized survival increased considerably at 1 year, but increased less at 5 years after diagnosis. This increase was observed at ages 60 and 70, but was less obvious at age 80. There was little difference in net survival from lung cancer between European Latin countries, particularly in the more recent years. However, survival was slightly lower in Spain and Portugal than in France, Italy, Belgium and Switzerland. High-resolution studies with data on treatment, stage at diagnosis and comorbidities are needed to understand the reasons for these differences.
AB - Survival is a key measure of the effectiveness of a healthcare system. European Latin countries have some similarities in their health systems; it is thus interesting to examine their differences in survival from cancer, here, lung cancer. The aim of the SUDCAN collaborative study was to compare the trends in the 1- and 5-year net survival from lung cancer and the trends in the excess mortality rates between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland). The data were extracted from the EUROCARE-5 database. First, the net survival was studied over the 2000-2004 period using Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. The analyses were carried out using a flexible excess rate modelling. Overall, the 1-year net survival from lung cancer ranged between 36 (Spain) and 43% (Belgium and Switzerland) and the 5-year net survival ranged between 11 (Spain) and 15% (Belgium and Switzerland). Between 1992 and 2004, the age-standardized survival increased considerably at 1 year, but increased less at 5 years after diagnosis. This increase was observed at ages 60 and 70, but was less obvious at age 80. There was little difference in net survival from lung cancer between European Latin countries, particularly in the more recent years. However, survival was slightly lower in Spain and Portugal than in France, Italy, Belgium and Switzerland. High-resolution studies with data on treatment, stage at diagnosis and comorbidities are needed to understand the reasons for these differences.
KW - Cancer registries
KW - Europe
KW - Excess mortality rate
KW - Lung cancer
KW - Net survival
KW - Trend analysis
UR - http://www.scopus.com/inward/record.url?scp=85010210728&partnerID=8YFLogxK
U2 - 10.1097/CEJ.0000000000000299
DO - 10.1097/CEJ.0000000000000299
M3 - Article
C2 - 28005608
AN - SCOPUS:85010210728
SN - 0959-8278
VL - 26
SP - S70-S76
JO - European Journal of Cancer Prevention
JF - European Journal of Cancer Prevention
IS - Trends in cancer net survival in six European Latin Countries...
ER -
